Investigational Drug Information for Etrumadenant
✉ Email this page to a colleague
What is the development status for investigational drug Etrumadenant?
Etrumadenant is an investigational drug.
There have been 18 clinical trials for Etrumadenant.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 4th 2021.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Colorectal Neoplasms. The leading clinical trial sponsors are Arcus Biosciences, Inc., Infinity Pharmaceuticals, Inc., and Memorial Sloan Kettering Cancer Center.
Summary for Etrumadenant
| US Patents | 0 |
| International Patents | 24 |
| US Patent Applications | 17 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2021-08-04) |
| Vendors | 40 |
Recent Clinical Trials for Etrumadenant
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | Memorial Sloan Kettering Cancer Center | Phase 2 |
| A Study of Novel Treatment Combinations in Patients With Lung Cancer | Gilead Sciences | Phase 2 |
| A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | M.D. Anderson Cancer Center | Phase 2 |
Clinical Trial Summary for Etrumadenant
Top disease conditions for Etrumadenant
Top clinical trial sponsors for Etrumadenant
US Patents for Etrumadenant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Etrumadenant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Etrumadenant | Argentina | AR110763 | 2037-01-20 | ⤷ Sign Up |
| Etrumadenant | Australia | AU2018210272 | 2037-01-20 | ⤷ Sign Up |
| Etrumadenant | Australia | AU2022203515 | 2037-01-20 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
